Sign In
Buy NKTR
$72.76
+2.17 (+3.07%)
At Close: Aug 04, 2026
Nektar Therapeutics (NKTR) Stock Slides Despite Analyst Optimism On Alopecia Data
04:19pm, Monday, 22'nd Dec 2025
Nektar Therapeutics stock is trading lower Monday afternoon as the market continues to assess mixed topline results from the Phase 2b REZOLVE-AA trial of rezpegaldesleukin.
Nektar Therapeutics: Alopecia Update And A Look At The Road Ahead For Rezpeg
04:49pm, Wednesday, 17'th Dec 2025
Nektar Therapeutics's results from REZOLVE-AA, a trial of rezpegaldesleukin in alopecia areata, have failed to stimulate a rally in the stock. Even with concerns about statistical significance in the
Nektar Therapeutics (NKTR) Discusses Topline Results From REZOLVE-AA Phase 2b Study of rezpegaldesleukin in Alopecia Areata Transcript
Nektar Alopecia Trial Misses Endpoint, Hits Significance After Patient Exclusion
11:30am, Tuesday, 16'th Dec 2025
Nektar Therapeutics (NASDAQ: NKTR) on Tuesday revealed topline results from the 36-week induction treatment period of the Phase 2b REZOLVE-AA trial of investigational rezpegaldesleukin.
SAN FRANCISCO , Dec. 15, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will h
Here's Why Nektar Therapeutics (NKTR) is a Great Momentum Stock to Buy
01:01pm, Monday, 08'th Dec 2025
Does Nektar Therapeutics (NKTR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:00pm, Friday, 05'th Dec 2025
SAN FRANCISCO , Dec. 5, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified st
Contrasting Nektar Therapeutics (NASDAQ:NKTR) & Pivotal Therapeutics (OTCMKTS:PVTTF)
01:40am, Thursday, 04'th Dec 2025
Pivotal Therapeutics (OTCMKTS:PVTTF - Get Free Report) and Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the t
Wall Street Analysts Believe Nektar (NKTR) Could Rally 64.53%: Here's is How to Trade
10:56am, Monday, 01'st Dec 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 64.5% in Nektar (NKTR). While the effectiveness of this highly sought-after metric is questionable, the positiv
Does Nektar (NKTR) Have the Potential to Rally 62.75% as Wall Street Analysts Expect?
10:56am, Thursday, 13'th Nov 2025
The consensus price target hints at a 62.8% upside potential for Nektar (NKTR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r
Nektar Therapeutics: Balancing The Immune System To Potential Blockbuster Markets
10:59am, Wednesday, 12'th Nov 2025
Nektar Therapeutics (NKTR) develops novel immunomodulatory drugs targeting autoimmune diseases and oncology, leveraging its expertise in immune system regulation. Recent Phase 2 results for Atopic Der
Nektar Therapeutics: Cautiously Positive Moving Into Phase 2b Readout
12:39am, Wednesday, 12'th Nov 2025
Nektar Therapeutics has pivoted from oncology to focus on autoimmune and inflammatory diseases, with Rezpegaldesleukin (Rezpeg) as its lead asset. NKTR's value now centers on Treg biology, advancing R
Statistically significant and clinically meaningful improvements in mean ACQ-5 scores were reported at week 16 versus placebo in patients who had atopic dermatitis and a history of asthma Extended dos
Nektar Therapeutics (NKTR) Q3 2025 Earnings Call Transcript
04:26pm, Friday, 07'th Nov 2025
Nektar Therapeutics ( NKTR ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Vivian Wu Howard W. Robin - CEO, President & Director Jonathan Zalevsky - Senior VP and Chief Resea
Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y
11:16am, Friday, 07'th Nov 2025
NKTR posts a narrower Q3 loss and a revenue beat, while its rezpeg program advances with key phase IIb milestones.
